Tyra Bioscience (TYRA)
NASDAQ:TYRA
TYRA Stock Chart & Stats
$35.27
-$0.12(-0.75%)
At close: 4:00 PM EST
$35.27
-$0.12(-0.75%)
Day’s Range― - ―
52-Week Range$7.80 - $40.65
Previous CloseN/A
Volume80.11K
Average Volume (3M)370.94K
Market Cap
$1.92B
Enterprise Value$1.82B
Total Cash (Recent Filing)$256.00M
Total Debt (Recent Filing)$5.81M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Apr 30, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding53,867,115
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.70K
Enterprise Value/Ebitda-15.26
Forecast
1Y Price Target
$51.00Price Target Upside44.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyEarly clinical results indicate dabogratinib produced higher tumor response rates and substantially fewer adverse events than prior FGFR inhibitors, supporting the potential for broader clinical adoption in FGFR3-driven diseases.
Patient Convenience And Market DifferentiationAn effective oral FGFR3-selective therapy may allow many patients to avoid kidney-removing surgery and replace frequent urethral instillations, creating a clear convenience advantage that could drive market uptake.
Regulatory PathwayA planned pivotal-intent trial in low-grade upper tract urothelial carcinoma aims to support a first approval for dabogratinib, which would represent a major regulatory and commercial milestone if successful.
Bears Say
Clinical Development UncertaintyCompletion of enrollment in an early-stage metastatic study without available full results leaves uncertainty about dabogratinib's activity in advanced disease and increases program risk.
Durability Of Response RiskAn initial complete response signal in non-muscle-invasive bladder cancer may not translate into durable benefit, and lack of sustained responses would materially limit the program's upside.
Financial Reliance On Clinical SuccessOngoing operating losses increase reliance on positive clinical readouts to justify valuation, creating downside risk if upcoming trial outcomes fail to meet expectations.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $7.80 and its highest was $40.65 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $1.92B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Apr 30, 2026 which is in 14 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on Mar 02, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.532 by -$0.038.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.59.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 53,867,115 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.532. Following the earnings report the stock price went up 1.507%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (44.60% Upside)
$51.00 (44.60% Upside)
Hedge Fund Trend
Increased
By 951.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $528.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
-34.75%
Trailing 12-Months
Asset Growth
-20.69%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$51.00
▲(44.60% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―